Table 2 Variables assignment in clinical survival model and clinical-molecular survival model.

From: Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis

Survival model

Variables

β

HR (95%CI)

Score assigned

Risk category

Clinical survival model

Age ≥ 65 years

0.877

2.405(1.335–4.334)

1

0-1: low risk

2–3: intermediate risk

≥4: high risk

IPSS-R cytogenetic category intermediate/poor/very poor

0.715

2.044 (1.072–3.896)

1

Hemoglobin < 80 g/L

0.577

1.780 (1.013–3.126)

1

Platelet count ≥ 800 × 10E + 9/L

0.679

1.971(1.065–3.648)

1

BM RS < 15%

1.218

3.381 (1.777–6.433)

2

Clinical-molecular survival model

Age ≥ 65 years

0.599

1.820 (0.823–4.025)

1

0–1: low risk

2–3: intermediate risk

≥4: high risk

IPSS-R cytogenetic category intermediate/poor/very poor

0.814

2.256 (0.919–5.542)

1

Hemoglobin < 80 g/L

0.561

1.752 (0.806–3.811)

1

Platelet count ≥ 800 × 10E + 9/L

0.682

1.978 (0.883–4.429)

1

BM RS < 15%

1.230

3.419 (1.600–7.305)

2

SETBP1 mutation

1.353

3.869 (1.056–14.172)

2

SRSF2 mutation

1.562

4.770 (1.311–17.350)

3

  1. β regression coefficients, HR hazard ratio, CI Confidence Interval, IPSS-R revised international prognostic scoring system, BM bone marrow, RS ring sideroblasts.
Back to article page